Free Trial

Citigroup's Rating of BridgeBio Pharma on 7/16/2026

On July 16, 2026, Citigroup updated its outlook on BridgeBio Pharma (NASDAQ:BBIO) with the action "Boost Price Target", setting a price target of $93.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Citigroup Inc.

DateCompanyAction
10/15/2026
Aker BP ASA stock logo
DETNF
Aker BP ASA
Reiterated Rating
10/15/2026
ASML Holding N.V. stock logo
ASML
ASML
Reiterated Rating
10/15/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Reiterated Rating
10/15/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price Target
10/15/2026
Meta Platforms, Inc. stock logo
META
Meta Platforms
Boost Price Target
10/15/2026
The Beauty Health Company stock logo
SKIN
Beauty Health
Reiterated Rating
More Ratings From Citigroup Inc.